Neo­vacs signs €65M Chi­na deal; An­oth­er biotech CEO chat­ters on about a pos­si­ble buy­out

• Paris-based Neo­vacs says it signed up BioSense Glob­al for a €65 mil­lion deal cov­er­ing the de­vel­op­ment of its IFNα Ki­noid vac­cine to treat lu­pus and der­mato­myosi­tis in the Chi­nese mar­ket. BioSense CEO Andy Li says he will launch a Phase III in Chi­na for the drug, pro­vid­ed it clears an on­go­ing Phase IIb tri­al con­duct­ed by Neo­vacs. The cash cov­ers an up­front and mile­stones, though the an­nounce­ment didn’t break out the prices.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER